Celgene Corporation  

(Public, NASDAQ:CELG)   Watch this stock  
Find more results for CELG
117.66
+0.67 (0.57%)
Pre-market: 118.30 +0.64 (0.54%)
Mar 27, 6:00AM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 114.02 - 119.39
52 week 66.85 - 129.06
Open 115.28
Vol / Avg. 17.00/5.47M
Mkt cap 93.66B
P/E 49.10
Div/yield     -
EPS 2.40
Shares 800.59M
Beta 1.05
Inst. own 83%
Apr 22, 2015
Q1 2015 Celgene Corp Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Mar 11, 2015
Celgene Corp at Barclays Healthcare Conference
Mar 4, 2015
Celgene Corp at Cowen Health Care Conference
Feb 24, 2015
Celgene Corp at RBC Healthcare Conference
Feb 11, 2015
Celgene Corp at Leerink Global Healthcare Conference
Jan 29, 2015
Q4 2014 Celgene Corp Earnings Release
Jan 29, 2015
Q4 2014 Celgene Corp Earnings Call
Jan 12, 2015
Celgene Corp at JPMorgan Healthcare Conference - Q&A Session
Jan 12, 2015
Celgene Corp at JPMorgan Healthcare Conference - Webcast
Jan 12, 2015
Preliminary 2014 Celgene Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 29.44% 26.07%
Operating margin 36.04% 32.79%
EBITD margin - 38.35%
Return on average assets 14.59% 13.02%
Return on average equity 40.06% 33.02%
Employees 6,012 -
CDP Score - 85 B

Address

86 Morris Ave
SUMMIT, NJ 07901-3915
United States - Map
+1-908-6739000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha

Description

Celgene Corporation is a global biopharmaceutical company primarily engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. The Company�s commercial stage products include REVLIMID, VIDAZA, ABRAXANE, POMALYST/IMNOVID, THALOMID, ISTODAX and azacitidine for injection. The Company�s preclinical and clinical-stage pipeline includes Oral anti-inflammatory agents, OTEZLA (apremilast); Next generation thalidomide analogues, CC-122 and CC-220; Cellular therapies, PDA-001 and PDA-002; CC-486; Sotatercept and ACE-536; mTOR pathway inhibitors, CC-223 and CC-115; Epigenetic modifiers, EPZ-5676 and CC-292. Its subsidiaries are Celgene Avilomics Research and Celgene Cellular Therapeutics. The Company collaborated with Acceleron Pharma, Inc. (Acceleron) to develop sotatercept and ACE-536 to treat anemia in patients with rare blood disorders.

Officers and directors

Robert J. Hugin Chairman of the Board, President, Chief Executive Officer
Age: 59
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Mark J. Alles President, Chief Operating Officer
Age: 55
Bio & Compensation  - Reuters
Peter N. Kellogg Chief Financial Officer, Executive Vice President
Age: 58
Bio & Compensation  - Reuters
Jacqualyn A Fouse Ph.D. President - Hematology & Oncology
Age: 52
Bio & Compensation  - Reuters
Tuomo Patsi President - Europe, Middle East and Africa (EMEA)
Bio & Compensation  - Reuters
Scott Smith President - Inflammation & Immunology
Bio & Compensation  - Reuters
Perry A. Karsen Chief Operations Officer, Executive Vice President
Age: 59
Bio & Compensation  - Reuters
Lawrence V. Stein Executive Vice President, General Counsel, Corporate Secretary
Age: 64
Bio & Compensation  - Reuters
Thomas O. Daniel M.D. Executive Vice President, President - Research and Early Development
Age: 60
Bio & Compensation  - Reuters
Michael D. Casey Lead Independent Director
Age: 68
Bio & Compensation  - Reuters